Talk Title: Innovative Multiple Tech & Platforms Empower Antibody Discovery
Speaker: Dr.Long Xu, Director, R&D Strategy at Biointron
Biointron is excited to announce our upcoming collaborative webinar with the Antibody Society, scheduled for September 26th, 2023. This webinar will feature our esteemed speaker, Dr. Long Xu, Director of R&D at Biointron. Dr. Xu will delve into the captivating topic of "Innovative Multiple Tech & Platforms Empower Antibody Discovery," providing attendees with a rich and informative exploration of the latest trends and advancements in antibody discovery. This webinar presents a not-to-be-missed opportunity for professionals, scholars, and all those passionate about the evolving landscape of antibody development, offering a chance to deepen their knowledge and engage with groundbreaking concepts in this vital field.
Topic: Innovative Multiple Tech & Platforms Empower Antibody Discovery
Abstract
Over the past two decades, antibody drugs have seen remarkable success, with antibody-based blockbuster drugs increasingly capturing market share year after year.
However, the field of antibody discovery still faces significant hurdles, including poor tissue permeability, challenges in module coupling, and issues with immunogenicity. To tackle these problems, this presentation explores the use of VHH antibodies as a promising solution. We'll walk you through a comprehensive case study, from initial antibody discovery to functional assays, antibody optimization, and all the way to application. There are also additional case studies that demonstrate how to apply new technologies and platforms to solve common problems in antibody discovery.
Speaker Bio
Dr.Long Xu earned his undergraduate degree from Nanjing University in China and completed his PhD at Boston University in the United States.
With over a decade of experience, Dr. Xu worked at Washington University in St. Louis, Lighting Research Center, and other internationally renowned institutions. His research spans multiple disciplines within life sciences and health, including DNA damage and repair, DNA photoreactivation, lighting and health, etc.
In 2022, he joined the Biointron team, focusing on the establishment of various high-quality antibody technology platforms, and dedicated to the discovery, optimization, and application research of antibodies.
About Biointron
Founded in 2012 and certified with ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech/pharmaceutical companies.
Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 1,200 biotech and pharma companies worldwide.
We provide a one-stop solution for antibody discovery and optimization – offering services like VHH antibody development, hybridoma sequencing, antibody humanization, antibody affinity maturation, single B-cell antibody screening, and more.
Additionally, Biointron holds global re-licensing rights for ECACC's CHO-K1. Our CHOK1BN cell strain has been filed in the US FDA’s DMF system and meets international multi-center trial standards, with projects already in advanced clinical stages successfully.
Innovative Multiple Tech & Platforms Empower Antibody Discovery
Free Download
Biointron's SVP of R&D, Lei Shi, PhD, discussed the processes of accelerating early discovery through HTP and high-speed antibody production during the Antibody Engineering & Therapeutics US 2023 conference in San Diego. Below is a summary of the talk.
ScientistとScience Exchangeとのご利用可能です。
